On Monday, Shares of Morgan Stanley (NYSE:MS), gained 2.74% to $32.29.
Morgan Stanley Private Wealth Administration recently declared the launch of its new coffee table book If…Stories of Philanthropy, a publication that illustrates the extraordinary power of philanthropy through the stories of seven remarkable philanthropic clients.
From empowering women in developing countries to fighting addiction here in the United States, the philanthropists featured in the book are changing the world one initiative at a time. Showcased clients comprise humanitarians Christy Turlington Burns, founder of Every Mother Counts; Mary Fisher, founder of 100 Good Deeds; Molly Gochman, ambassador to The Polaris Project; Terry Lazin, founder of The Lazin Animal Foundation; Francine LeFrak, founder of Same Sky; Gary Mendell, founder of Shatterproof; and Elizabeth Carlock and Kevin Phillips; Executive Director and CEO, respectively, of The Phillips Foundation.
Morgan Stanley is a financial holding company. Through its auxiliaries and associates, the Company provides a variety of products and financial services to a group of clients and customers, counting corporations, governments, financial institutions and individuals.
Shares of Celgene Corporation (NASDAQ:CELG), inclined 0.15% to $116.62, during its last trading session.
Cryoport, Inc. (CYRX) declared the appointment of Robert Hariri, MD, PhD to its Board of Directors.
Dr. Hariri is the Chairman, Founder and Chief Scientific Officer of Celgene Cellular Therapeutics, one of the world’s largest human cellular therapeutics companies and wholly owned partner of Celgene Corporation (CELG). He has pioneered the use of stem cells and biomaterials to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering.
Dr. Hariri is a visionary scientist, surgeon, aviator and entrepreneur. He has over 100 issued and pending patents; authored over 100 published chapters, articles and abstracts; and is most recognized for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumor necrosis factor).
Celgene Corporation (Celgene), together with its auxiliaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.
Shares of Exelixis, Inc. (NASDAQ:EXEL), declined -0.17% to $5.90, during its last trading session.
Exelixis, declared positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in formerly untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis’ collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically noteworthyand clinically meaningful improvement in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as contrast to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are predictable later this year. These data will be the subject of a presentation at an forthcoming medical meeting.
Exelixis declared the first regulatory approval of cobimetinib in Switzerland in August 2015. U.S. and EU regulatory applications sponsored by Genentech and Roche, respectively, are presently under review. In the United States, the Prescription Drug User Fee Act action date is November 11, 2015. In the EU, Roche anticipates a regulatory decision by the end of this year following a positive opinion from the European Committee for Medicinal Products for Human Use declared in late September.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States.
Finally, Stratasys, Ltd. (NASDAQ:SSYS), ended its last trade with 6.58% gain, and closed at $28.35. The stock traded as high as $28.75 and last traded at $28.64, with a volume of 735,045 shares traded. The stock had formerly closed at $26.60.
The company’s market capitalization is $1.46 billion. The firm’s 50-day moving average is $28.90 and its 200-day moving average is $38.01.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
